What do systematic reviews say?

Any antifungal intervention for the treatment of oral candidiasis vs Placebo, no treatment, or another active antifungal intervention

The review found no eligible studies for this question.

• Interventions for treating oral candidiasis for patients with cancer receiving treatment 2010 · Cochrane All outcomes
  None of the studies reported: relief of pain, relief of dysphagia, incidence of systemic infection, amount of analgesia, days stay in hospital, cost of oral care, patient quality of life.
  0 studies
  No studies found

Prophylactic aciclovir (oral or intravenous) vs Prophylactic valaciclovir (oral)

• Interventions for the prevention and treatment of herpes simplex virus in patients being treated for cancer 2009 · Cochrane All outcomes
  Only one trial reported on the cost of prophylaxis for HSV (Liesveld 2002). The reported mean pharmacy costs for those randomised to receive aciclovir were $1080 compared to $320 for those initially randomised to…
  1 study · 30 participants
  GRADE not reported

Aciclovir (oral or intravenous) for treatment vs placebo

The review found no eligible studies for this question.

• Interventions for the prevention and treatment of herpes simplex virus in patients being treated for cancer 2009 · Cochrane All outcomes
  For the treatment comparison (aciclovir versus placebo), no data were available for recurrence of lesions, amount of analgesia, days of stay in hospital, cost of oral care or patient quality of life.
  0 studies
  No studies found

Antifungal drugs absorbed from GI tract (fluconazole, ketoconazole, itraconazole) vs placebo or no treatment

The review found no eligible studies for this question.

• Interventions for preventing oral candidiasis for patients with cancer receiving treatment 2007 · Cochrane All outcomes
  No trial reported this planned secondary outcome for any comparison in this review
  Studies not reported
  No studies found